INTERVIEW: Scott Reese, CEO at US-based C-Beyond Health, says patient-doctor dialog is critical to successful treatment with CBD.
HempToday: You describe C-Beyond Health as being in the “patient directed” cannabinoid market. What does that really mean?
Scott Reese: First off. CBD is certainly the most prevalent and recognizable of the hemp derived cannabinoids. However the future lies in exacting combinations of the right cannabinoids in the right ratios to achieve health outcomes for particular conditions. “Patient directed,” to us, means bringing forth advanced botanical and medicinal chemistry solutions using the right cannabinoids to treat particular conditions. We start with patient needs assessments as the first phase of our product development cycle.
These patient-need assessments are conducted by leading physicians in that particular condition category. For instance, in menopause, we work with a leading women’s health medical director to understand the specific symptomatology, pathology and psychographic profiles of the patient. We then transfer that knowledge and data to leading formulators to design the cannabinoid profiles and delivery methods for these products.